It’s time to make PrEP available to all who need it

Edited September 2018

NAM, alongside a large number of HIV organisations and many community activists, are agreed that a 10,000 place PrEP trial was never large enough to meet demand. For this reason, alongside 31 other organisations, we are calling on NHS England and local authorities to ensure the routine availability of pre-exposure prophylaxis (PrEP) on the NHS in England by 1 April 2019.

That’s why we’ve released a joint community statement, We need PrEP on the NHS now.



Cost-effectiveness analyses compare the financial cost of providing health interventions with their health benefit in order to assess whether interventions provide value for money. As well as the cost of providing medical care now, analyses may take into account savings on future health spending (because a person’s health has improved) and the economic contribution a healthy person could make to society.


To eliminate a disease or a condition in an individual, or to fully restore health. A cure for HIV infection is one of the ultimate long-term goals of research today. It refers to a strategy or strategies that would eliminate HIV from a person’s body, or permanently control the virus and render it unable to cause disease. A ‘sterilising’ cure would completely eliminate the virus. A ‘functional’ cure would suppress HIV viral load, keeping it below the level of detection without the use of ART. The virus would not be eliminated from the body but would be effectively controlled and prevented from causing any illness. 

The current three-year PrEP IMPACT trial isn’t fit for purpose. The trial is capped at 10,000 places and within just eight months over 7000 of these are taken. A survey of PrEP users, taken before the trial opened, indicated that the demand would outstrip the limited number of places.

Many participating clinics are now closed to gay and bisexual men, which means people are being turned away from clinics who are in need of PrEP – some of whom have contracted HIV as a result.

PrEP is almost 100% effective when taken as prescribed. It’s cost effective when measured against the cost of lifelong HIV treatment and care. PrEP has the power to stop many people from becoming HIV positive.

Matthew Hodson, NAM’s Executive Director, said, “Despite all of the advances in treatment we have seen there is still no cure for HIV infection. If you live with HIV you need to take daily medication to remain well. PrEP can be limited to those periods when people are at greatest risk of acquiring HIV, and is therefore effectively much cheaper.”

NHS England and local authority commissioners must start the process now to ensure PrEP is routinely available in sexual health clinics by 1 April 2019 at the latest. We believe the PrEP IMPACT trial should continue alongside routine commissioning.

Hodson added, “We should not let tradition alone dictate how HIV is prevented. We now have all the tools that we need to effectively end new HIV infections in the UK. Scotland and Wales are on board, but England is lagging behind. PrEP’s effectiveness has been proven and it’s urgent that it is added to our HIV prevention armoury. This is no time for hesitation or procrastination. PrEP should be available to anyone who needs it now.”

Read the full community statement and show your support on social media using the hashtag #PrEPNow.